<DOC>
	<DOCNO>NCT02282579</DOCNO>
	<brief_summary>The purpose retrospective observational study analyze effect target therapy administer second-line treatment failure pazopanib well increase amount information available efficacy safety pazopanib first-line therapy practice usual clinical treatment metastatic Renal Carcinoma .</brief_summary>
	<brief_title>Spanish Retrospective Study Evaluate Efficacy Safety Targeted Therapies After Pazopanib First-line Therapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Patients ≥ 18 . Metastatic renal cell cancer histology . Patients treat pazopanib metastatic cell renal cancer outside context clinical trial ( clinical practice ) Spanish center 1 April 2011 30 June 2014. shall include patient receive pazopanib firstline treatment participate center , whether experienced treatment failure pazopanib still firstline treatment . The inclusion patient also allow received cytokine firstline treatment follow pazopanib well patient receive sunitinib firstline treatment change pazopanib toxicity intolerance , provide received cycle sunitinib . Centers agree participate must commit : · Include patient meet inclusion criterion reduce possible selection bias . Because supply pazopanib Hospital pharmacy service ( outside hospital ) , identification patient perform hospital pharmacy record participate center . Patients receive pazopanib clinical trial treatment second line , exception note . Patients diagnosis / treatment malignancy importance Cell renal cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>